AlphaYou
Overview
Smart money at a glance
Filings to Sep 27, 2026Net selling: insiders sold $30M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net buying of $30K to $100K in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$30M netNet selling
- CongressSTOCK Act, last 180 days
- +$30K to +$100K netNet buying
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 3 added, 4 cutMore cutting
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 26- Open
- $148.06
- 52-wk high
- $156.00
- High
- $149.98
- 52-wk low
- $75.80
- Low
- $147.48
- Prev close
- $147.98
- Mkt cap
- $367.07B
- P/E
- 120.0x
- Volume
- 8.29M
- Fwd P/E
- 15.3x
- Beta
- 0.23
- Div yield
- 2.24%
- P/S
- 5.5x
- P/B
- 8.7x
- Profit margin
- +4.8%
- Op margin
- -0.2%
- ROE
- +7.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about MRK filings
Are insiders buying or selling Merck & Company Inc (MRK) stock?
Net selling: insiders sold $30M and bought $0 of MRK stock on the open market in the 90 days to Sep 27, 2026, according to SEC Form 4 filings. The largest was Zachary, Jennifer (EVP, General Counsel), who sold $10.7M. The latest filing was on Aug 13, 2026.
Which members of Congress have traded MRK recently?
Rep. Maria Elvira Salazar (R) bought $15K to $50K on Aug 19, 2026, disclosed 21 days later. Rep. Maria Elvira Salazar (R) bought $15K to $50K on Aug 19, 2026, disclosed 21 days later. In total, 1 member disclosed 2 MRK trades with trade dates in the last 180 days, filed a median 21 days after trading.
How current is this MRK smart-money data?
This summary uses filings available on Sep 27, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (1)
- QR
Qube Research
$134.2M
bought
Sells/Trims (2)
- BA
Balyasny
$210.8M
trimmed
- MI
Millennium
$164.9M
trimmed
What insiders are doing
What Congress is doing
How top traders are positioned
No tracked top-trader positions in MRK right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 50.0% above what analysts expected.
Earnings per share
-$0.26 expected
Full Year 2026 guidance
$66.30B to $67.30B
No comparable estimate
Reports Oct 29, 2026, in 32 days
Estimates as of Sep 27, 2026
EPS expected
$2.01 to $2.34
Revenue expected
16 analysts
Last 30 days
Analysts cutting estimates
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $17.18B | $16.32B | $16.29B | $16.61B |
| Cost of what it sold | $4.19B | $4.82B | $2.94B | $4.39B |
| Gross profit | $12.99B | $11.51B | $13.34B | $12.21B |
| What it spent | ||||
| Research and development | $3.55B | $2.50B | $12.56B | $9.74B |
| Sales and admin | $2.63B | $2.85B | $2.70B | $2.90B |
| Other operating costs | -$659.0M | — | — | $250.0M |
| Total operating expenses | $5.53B | $5.35B | $15.23B | $12.89B |
| What was left | ||||
| Operating profit | $7.46B | $6.16B | -$1.88B | -$683.0M |
| Interest on debt | $327.0M | $411.0M | $479.0M | $525.0M |
| Profit before tax | $6.75B | $3.42B | -$3.53B | -$683.0M |
| Tax | $958.0M | $458.0M | $709.0M | $654.0M |
| Net profit | $5.79B | $2.96B | -$4.24B | -$1.33B |
| EBITDA | $8.14B | $6.30B | -$2.02B | $1.43B |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Empery Digital Inc. SEC Filing (Sep 25, 2026)
NeutralSep 26Merck, Daiichi withdraw ifinatamab FDA application
BearishSep 25Merck, Daiichi Sankyo withdraw US application for lung cancer therapy
BearishSep 25REGENXBIO reports three-year ALTITUDE DRSS data
NeutralSep 25Merck & Co. stock is last at USD 147.97, down 0.01 percent in New York trading
NeutralSep 25Is Celldex Therapeutics, Inc. (CLDX) the Healthcare Stocks Stock Everyone's About to Talk About?
Leans bullishSep 25Moderna Stock Reached New 52-Week High: What's Happening?
NeutralSep 25Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study
Leans bullishSep 25
Macro
22 macro signals shaping MRK right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results